Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGTXOTCMKTS:CVSINYSE:JATT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGTXCognition Therapeutics$0.56-2.7%$0.33$0.22▼$2.54$34.90M0.883.01 million shs4.97 million shsCVSICV Sciences$0.04-2.3%$0.03$0.02▼$0.06$7.11M0.6227,471 shs72,081 shsJATTJATT Acquisition$1.13+0.9%$1.17$7.80▼$12.38$19.49MN/A41,322 shs129,512 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGTXCognition Therapeutics+27.49%+86.83%+96.00%+80.42%-69.70%CVSICV Sciences+7.07%+6.49%+55.12%+30.46%-29.64%JATTJATT Acquisition0.00%+7.62%-10.32%+9.71%-67.71%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCGTXCognition Therapeutics2.7976 of 5 stars3.53.00.00.02.41.70.6CVSICV SciencesN/AN/AN/AN/AN/AN/AN/AN/AJATTJATT AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGTXCognition Therapeutics 3.00Buy$2.83403.26% UpsideCVSICV Sciences 0.00N/AN/AN/AJATTJATT Acquisition 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CVSI, CGTX, and JATT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/26/2025CGTXCognition TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.005/27/2025CGTXCognition TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.00 ➝ $3.005/8/2025CGTXCognition TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $4.00(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGTXCognition TherapeuticsN/AN/AN/AN/A$0.31 per shareN/ACVSICV Sciences$15.70M0.45N/AN/A$0.01 per share3.85JATTJATT AcquisitionN/AN/A$0.04 per share27.08($0.53) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGTXCognition Therapeutics-$33.97M-$0.74N/AN/AN/AN/A-194.42%-115.14%8/6/2025 (Estimated)CVSICV Sciences-$2.39MN/A0.00∞N/A-12.25%-89.43%-22.75%N/AJATTJATT Acquisition$6.85MN/A0.00∞N/AN/A-49.58%2.84%N/ALatest CVSI, CGTX, and JATT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025CGTXCognition Therapeutics-$0.12-$0.14-$0.02-$0.14N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCGTXCognition TherapeuticsN/AN/AN/AN/AN/ACVSICV SciencesN/AN/AN/AN/AN/AJATTJATT AcquisitionN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGTXCognition TherapeuticsN/A2.092.09CVSICV Sciences0.261.140.30JATTJATT AcquisitionN/A0.150.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGTXCognition Therapeutics43.35%CVSICV SciencesN/AJATTJATT Acquisition47.97%Insider OwnershipCompanyInsider OwnershipCGTXCognition Therapeutics14.40%CVSICV Sciences1.30%JATTJATT Acquisition20.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGTXCognition Therapeutics2061.99 million53.07 millionNot OptionableCVSICV Sciences70184.79 million182.39 millionNot OptionableJATTJATT Acquisition317.25 million13.80 millionNot OptionableCVSI, CGTX, and JATT HeadlinesRecent News About These CompaniesCautious Hold Rating on Zura Bio Due to Efficacy Concerns and Competitive RisksDecember 25, 2024 | markets.businessinsider.comZura Bio (ZURA) Receives a Buy from Piper SandlerDecember 12, 2024 | markets.businessinsider.comCautious Outlook on Zura Bio: Neutral Rating Due to Clinical Challenges and Financial UncertaintyNovember 11, 2024 | markets.businessinsider.comThe Legend of Maula Jatt Review: Fawad Khan’s GoT-Coded War Epic Is Derivative, RIdden With ClichesOctober 4, 2024 | moneycontrol.comRelease of Fawad Khan’s Pakistani blockbuster ‘The Legend of Maula Jatt’ halted in IndiaOctober 4, 2024 | thehindu.comPakistani hit The Legend of Maula Jatt, starring Fawad Khan, Mahira Khan, not to release in India, confirms distributorOctober 4, 2024 | hindustantimes.comHIndia puts blockbuster Pakistani film on holdOctober 4, 2024 | bbc.co.uk"What is need to release Pakistani film in India?" Shiv Sena (UBT) opposes release of 'The Legend of Maula Jatt'September 22, 2024 | malaysiasun.comMShiv Sena (UBT) leader Anand Dubey opposes release of Pakistani film 'The Legend of Maula Jatt' in IndiaSeptember 22, 2024 | malaysiasun.comM‘Jatt & Juliet 3’ OTT release: When and where to watch the Diljit Dosanjh and Neeru Bajwa starrer rom-comAugust 27, 2024 | timesofindia.indiatimes.comBahdarpur Jatt Pin CodeApril 9, 2024 | indiatvnews.comINishikant Dubey, wife booked in med college acquisition caseMarch 31, 2024 | timesofindia.indiatimes.comSen. Fetterman says he will use ‘whatever tools are in the box’ to stop Japanese acquisition of U.S. SteelDecember 22, 2023 | pennlive.comPMicrosoft poised to close massive Activision Blizzard acquisition next weekOctober 9, 2023 | vg247.comVThe Legend of Maula Jatt to be released in cinemas on ThursdayJuly 8, 2023 | radio.gov.pkRPakistani film The Legend of Maula Jatt reunites South Asian communities in Antwerp BelgiumJune 15, 2023 | radio.gov.pkRZura Bio's Veteran Leadership Eyes Repeat Success, Confident Analyst Sees 150% UpsideMay 24, 2023 | msn.comI Am A Jaat. People Often Confuse Me For A Jatt. Here’s The Difference Between The TwoApril 28, 2023 | scoopwhoop.comSZura Bio Announces Appointment of Chief Scientific OfficerApril 16, 2023 | businesswire.comTalkTalk, the Issa brothers and AO: The 19 latest deals from across the North WestMarch 30, 2023 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCVSI, CGTX, and JATT Company DescriptionsCognition Therapeutics NASDAQ:CGTX$0.56 -0.02 (-2.73%) As of 11:05 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.CV Sciences OTCMKTS:CVSI$0.04 0.00 (-2.28%) As of 10:37 AM EasternCV Sciences, Inc. develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol (CBD) in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The company offers its products under the PlusCBD, ProCBD, HappyLane, CVAcute, CVDefense, and PlusCBD Pet brands in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, elect distributors, brick and mortar retailers, and select e-tailers. It is also developing cannabinoids intended to treat medical indications, including CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.JATT Acquisition NYSE:JATT$1.13 +0.01 (+0.89%) As of 07/3/2025JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AST SpaceMobile: Is Market Noise Drowning Out a $100M Signal? CoreWeave's $9 Billion Power Play for Core Scientific Taiwan Semiconductor May Profit from Chinese Manufacturing Issues Micron Insiders Sell But Investors Should Buy, Buy, Buy Believe the Hype? Can SoFi Maintain Its 3-Month Rally? Sizzling Insider Buys for Your High-Yield Watchlist Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
